Therapeutic Efficacy of Orally Delivered Doxorubicin Nanoparticles in Rat Tongue Cancer Induced by 4-Nitroquinoline 1-Oxide

Overview

Journal Adv Pharm Bull

Date 2015 Aug 4

PMID 26236659

Citations 1

Authors

Monir Moradzadeh Khiavi

Ahamd Rostami

Hamed Hamishekar

Mehran Mesgari Abassi

Amirala Aghbali

Roya Salehi

Bita Abdollahi

Soheila Fotoohi

Mahmud Sina

Affiliations

Soon will be listed here.

Abstract

Purpose: Oral cancer is one of the most significant cancers in the world, and squamous cell carcinoma makes up about 94% of oral malignancies. The aim of the present study was to compare the efficacy of doxorubicin plus methotrexate - loaded nanoparticles on tongue squamous cell carcinoma induced by 4NQO and compare it with the commercial doxorubicin and methotrexate delivered orally on seventy SD male rats.

Methods: 70 rats were divided into five groups. During the study, the animals were weighed by a digital scale once a week. Number of mortalities was recorded in the data collection forms. At the end of the treatment, biopsy samples were taken from rat tongues in order to evaluate the severity of dysplasia and the extent of cell proliferation. The results were analyzed using ANOVA, descriptive statistics and chi-square test.

Results: No statistically significant difference was found in the mean weight of five groups (p>0.05). No significant relationship was found between groups and mortality rate (P = 0. 39). In addition, there was a significant relationship between groups and the degree of dysplasia (P <0.001). The statistical analysis showed a significant relationship between groups and the rate of cell proliferation (p <0.001).

Conclusion: The results of the present study showed that the use of doxorubicin plus methotrexate - loaded nanoparticles orally had more therapeutic effects than commercial doxorubicin plus methotrexate.

Citing Articles

Assessment of the Blood Parameters, Cardiac and Liver Enzymes in Oral Squamous Cell Carcinoma Following Treated with Injectable Doxorubicin-Loaded Nano-Particles.

Khiavi M, Anvari E, Hamishehkar H, Abdal K Asian Pac J Cancer Prev. 2019; 20(7):1973-1977.

PMID: 31350953 PMC: 6745216. DOI: 10.31557/APJCP.2019.20.7.1973.

References

Joensuu H . Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol. 2008; 9(3):304. DOI: 10.1016/S1470-2045(08)70075-5. View

Tan P, Bay B, Yip G, Selvarajan S, Tan P, Wu J . Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol. 2004; 18(3):374-81. DOI: 10.1038/modpathol.3800254. View

Benival D, Devarajan P . Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm. 2011; 423(2):554-61. DOI: 10.1016/j.ijpharm.2011.11.035. View

Shiotani H, Denda A, Yamamoto K, Kitayama W, Endoh T, Sasaki Y . Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res. 2001; 61(4):1451-6. View

Arima Y, Nishigori C, Takeuchi T, Oka S, Morimoto K, Utani A . 4-Nitroquinoline 1-oxide forms 8-hydroxydeoxyguanosine in human fibroblasts through reactive oxygen species. Toxicol Sci. 2006; 91(2):382-92. DOI: 10.1093/toxsci/kfj161. View

Wang Q, Zhong Y, Yuan J, Shao L, Zhang J, Tang L . Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med. 2013; 11:192. PMC: 3765954. DOI: 10.1186/1479-5876-11-192. View

Mudshinge S, Deore A, Patil S, Bhalgat C . Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm J. 2013; 19(3):129-41. PMC: 3744999. DOI: 10.1016/j.jsps.2011.04.001. View

Milane L, Duan Z, Amiji M . Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One. 2011; 6(9):e24075. PMC: 3169576. DOI: 10.1371/journal.pone.0024075. View

Vered M, Yarom N, Dayan D . 4NQO oral carcinogenesis: animal models, molecular markers and future expectations. Oral Oncol. 2005; 41(4):337-9. DOI: 10.1016/j.oraloncology.2004.07.005. View

10.

Steiniger S, Kreuter J, Khalansky A, Skidan I, Bobruskin A, Smirnova Z . Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004; 109(5):759-67. DOI: 10.1002/ijc.20048. View

11.

Peer D . Harnessing RNAi nanomedicine for precision therapy. Mol Cell Ther. 2015; 2:5. PMC: 4452054. View

12.

Siegal T, Horowitz A, Gabizon A . Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg. 1995; 83(6):1029-37. DOI: 10.3171/jns.1995.83.6.1029. View

13.

Wohlfart S, Khalansky A, Bernreuther C, Michaelis M, Cinatl Jr J, Glatzel M . Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles. Int J Pharm. 2011; 415(1-2):244-51. DOI: 10.1016/j.ijpharm.2011.05.046. View

14.

Kalaria D, Sharma G, Beniwal V, Kumar M . Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2008; 26(3):492-501. DOI: 10.1007/s11095-008-9763-4. View

15.

Salehi R, Hamishehkar H, Eskandani M, Mahkam M, Davaran S . Development of dual responsive nanocomposite for simultaneous delivery of anticancer drugs. J Drug Target. 2014; 22(4):327-42. DOI: 10.3109/1061186X.2013.876645. View

16.

Sohrabi M, Soleimani J, Roshangar L, Vatansever S, Arbabi F, Khaki A . The effect of dietary and topical celecoxib on 4-nitroquinoline-1-oxide-induced lingual epithelium alternations in rat. J Pak Med Assoc. 2010; 59(11):769-74. View

17.

Valetti S, Mura S, Stella B, Couvreur P . Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice. J Nanobiotechnology. 2014; 11 Suppl 1:S6. PMC: 4029540. DOI: 10.1186/1477-3155-11-S1-S6. View

18.

Deng Z, Zhen Z, Hu X, Wu S, Xu Z, Chu P . Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy. Biomaterials. 2011; 32(21):4976-86. DOI: 10.1016/j.biomaterials.2011.03.050. View

19.

Couvreur P, Vauthier C . Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006; 23(7):1417-50. DOI: 10.1007/s11095-006-0284-8. View

20.

da Silva S, Ferlito A, Takes R, Brakenhoff R, Valentin M, Woolgar J . Advances and applications of oral cancer basic research. Oral Oncol. 2011; 47(9):783-91. DOI: 10.1016/j.oraloncology.2011.07.004. View